Historical Valuation
Neurosense Therapeutics Ltd (NRSN) is now in the Fair zone, suggesting that its current forward PS ratio of 54.71 is considered Fairly compared with the five-year average of -2.10. The fair price of Neurosense Therapeutics Ltd (NRSN) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：0.99
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Neurosense Therapeutics Ltd (NRSN) has a current Price-to-Book (P/B) ratio of -36.97. Compared to its 3-year average P/B ratio of -15.00 , the current P/B ratio is approximately 146.50% higher. Relative to its 5-year average P/B ratio of -10.37, the current P/B ratio is about 256.53% higher. Neurosense Therapeutics Ltd (NRSN) has a Forward Free Cash Flow (FCF) yield of approximately -42.96%. Compared to its 3-year average FCF yield of -27.66%, the current FCF yield is approximately 55.28% lower. Relative to its 5-year average FCF yield of -22.37% , the current FCF yield is about 92.04% lower.
P/B
Median3y
-15.00
Median5y
-10.37
FCF Yield
Median3y
-27.66
Median5y
-22.37
Competitors Valuation Multiple
AI Analysis for NRSN
The average P/S ratio for NRSN competitors is 9.63, providing a benchmark for relative valuation. Neurosense Therapeutics Ltd Corp (NRSN.O) exhibits a P/S ratio of 54.71, which is 467.83% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for NRSN
1Y
3Y
5Y
Market capitalization of NRSN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of NRSN in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is NRSN currently overvalued or undervalued?
Neurosense Therapeutics Ltd (NRSN) is now in the Fair zone, suggesting that its current forward PS ratio of 54.71 is considered Fairly compared with the five-year average of -2.10. The fair price of Neurosense Therapeutics Ltd (NRSN) is between to according to relative valuation methord.
What is Neurosense Therapeutics Ltd (NRSN) fair value?
NRSN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Neurosense Therapeutics Ltd (NRSN) is between to according to relative valuation methord.
How does NRSN's valuation metrics compare to the industry average?
The average P/S ratio for NRSN's competitors is 9.63, providing a benchmark for relative valuation. Neurosense Therapeutics Ltd Corp (NRSN) exhibits a P/S ratio of 54.71, which is 467.83% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Neurosense Therapeutics Ltd (NRSN) as of Jan 09 2026?
As of Jan 09 2026, Neurosense Therapeutics Ltd (NRSN) has a P/B ratio of -36.97. This indicates that the market values NRSN at -36.97 times its book value.
What is the current FCF Yield for Neurosense Therapeutics Ltd (NRSN) as of Jan 09 2026?
As of Jan 09 2026, Neurosense Therapeutics Ltd (NRSN) has a FCF Yield of -42.96%. This means that for every dollar of Neurosense Therapeutics Ltd’s market capitalization, the company generates -42.96 cents in free cash flow.
What is the current Forward P/E ratio for Neurosense Therapeutics Ltd (NRSN) as of Jan 09 2026?
As of Jan 09 2026, Neurosense Therapeutics Ltd (NRSN) has a Forward P/E ratio of -2.54. This means the market is willing to pay $-2.54 for every dollar of Neurosense Therapeutics Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Neurosense Therapeutics Ltd (NRSN) as of Jan 09 2026?
As of Jan 09 2026, Neurosense Therapeutics Ltd (NRSN) has a Forward P/S ratio of 54.71. This means the market is valuing NRSN at $54.71 for every dollar of expected revenue over the next 12 months.